You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR ATOGEPANT

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Atogepant

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02848326 ↗	Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention	Completed	Allergan	Phase 2/Phase 3	2016-09-06	This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.
NCT03700320 ↗	Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine	Completed	Allergan	Phase 3	2018-10-08	This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
NCT03777059 ↗	12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine	Completed	Allergan	Phase 3	2018-12-14	To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
NCT03855137 ↗	Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine	Active, not recruiting	Allergan	Phase 3	2019-03-11	This study will evaluate the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study includes a 12-week treatment period.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Atogepant

Condition Name

Chart
Table

Condition Name for Atogepant
Intervention	Trials
Episodic Migraine	9
Chronic Migraine	6
Migraine	3
Migraine, With or Without Aura	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Atogepant
Intervention	Trials
Migraine Disorders	17
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Atogepant

Trials by Country

Map
Table

Trials by Country for Atogepant
Location	Trials
United States	297
Japan	74
Poland	54
China	30
Canada	23
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Atogepant
Location	Trials
Florida	13
Texas	12
California	12
Utah	11
Ohio	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Atogepant

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Atogepant
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	14
Phase 2/Phase 3	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Atogepant
Clinical Trial Phase	Trials
Not yet recruiting	7
Completed	5
Enrolling by invitation	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Atogepant

Sponsor Name

Chart
Table

Sponsor Name for Atogepant
Sponsor	Trials
Allergan	13
AbbVie	5
Allergan Limited 1st Floor Marlow International, The Parkway Marlow, Buckinghamshire SL7 lYL	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Atogepant
Sponsor	Trials
Industry	18
Other	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.